Pharmaceutical availability of gliclazide from selected matrix formulation tablets

Medical Science Monitor

Volumn 11, Issue 6, 2005, Pages

  Hermann, Tadeusz W ^a   Dobrucki, Roman ^a   Piechocki, Stefan ^a   Resztak, Matylda ^a   Reh, Robert ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

In vitro release; Mean dissolution time (MDT); Modified release; Solubility

Indexed keywords

DIABEZIDUM; DIABREZIDE; DIAPREL; GLICLAZIDE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; IMMEDIATE DRUG RELEASE; MATRIX TABLET; MODIFIED DRUG RELEASE; SPECTROPHOTOMETER; SUSTAINED DRUG RELEASE;

ADMINISTRATION, ORAL; CALIBRATION; GLICLAZIDE; HYDROGEN-ION CONCENTRATION; HYPOGLYCEMIC AGENTS; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET; TABLETS;

EID: 21344437567     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Główka FK, Hermann TW, Zabel M: Bioavailability of gliclazide from some formulation tablets. Int J Pharm, 1998; 172: 71-77
2. Gumulka WS, Sasinowska-Motyl M: Studies on bioavailability of gliclazide. Terapia i Leki (Poland), 1998; 24/48: 105-9
3. Główka FK, Hermann TW, Zabel M: Bioavailability of gliclazide from formulation tablets diabezid from Jelfa, Poland. Terapia i Leki (Poland), 1997; 24/47: 229-35
4. Parfit K. editor. Martindale: The complete drug reference, XXXII. London: The Pharmaceutical Press: 1999: 320
5. Hong SS, Lee SH, Lee YJ et al: Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide. J Control Rel, 1998; 51: 185-92
6. Drouin P: Diamicron® MR once daily is effective and well tolerated in type 2 diabetes. A double-blind randomized multinational study. J Diab Comp, 2000; 14: 185-91
7. Delrat P, Paraire M, Jochemsen R: Complete bioavailability and lack of food effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers. Biopharm Drug Dispos, 2002; 23: 151-57
8. Campbell DB, Lavielle R, Nathan C: The mode of action and clinical pharmacology of gliclazide: a review. Diab Res, 1991; 14(Suppl.): S21-S36
9. McGavin J, Perry CM, Goa K: A modified-release gliclazide. Drugs, 2002; 62: 1357-64
10. Reza S, Quadir MA, Haider SS: Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery.J Pharm Pharmaceut Sci, 2003; 6: 282-91
11. Klottke MK, Rudnic EM: Tablet dosage forms. In: Banker GS, Rhodes CT, editors. Modern Pharmaceutics. 4th ed, New York, Basel: Marcel Dekker, 2002; 287-335
12. Harrower ADB: Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diab Comp, 1994; 8: 201-3